TD Asset Management
RARE icon

TD Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

TD Asset Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-81,964
Closed -$1.89M – 1287
2025
Q4 		$1.89M Sell
81,964
-15,034
-15% -$494K ﹤0.01% 996
2025
Q3 		$2.92M Sell
96,998
-26,886
-22% -$806K ﹤0.01% 887
2025
Q2 		$4.5M Sell
123,884
-14,600
-11% -$526K ﹤0.01% 780
2025
Q1 		$5.01M Buy
138,484
+45,000
+48% +$1.87M ﹤0.01% 786
2024
Q4 		$3.93M Sell
93,484
-75,600
-45% -$3.75M ﹤0.01% 840
2024
Q3 		$9.2M Buy
169,084
+20,000
+13% +$1.02M 0.01% 660
2024
Q2 		$6.13M Sell
149,084
-71,276
-32% -$3.04M 0.01% 717
2024
Q1 		$10.3M Sell
220,360
-1,000
-0.5% -$47.2K 0.01% 620
2023
Q4 		$10.6M Buy
221,360
+16,000
+8% +$620K 0.01% 607
2023
Q3 		$7.32M Buy
205,360
+87,580
+74% +$3.47M 0.01% 644
2023
Q2 		$5.43M Buy
117,780
+19,002
+19% +$881K 0.01% 718
2023
Q1 		$3.96M Sell
98,778
-31,372
-24% -$1.35M ﹤0.01% 798
2022
Q4 		$6.03M Sell
130,150
-132,214
-50% -$5.2M 0.01% 695
2022
Q3 		$10.6M Sell
262,364
-41,863
-14% -$2.15M 0.01% 571
2022
Q2 		$18.1M Sell
304,227
-54,114
-15% -$3.33M 0.02% 453
2022
Q1 		$26M Sell
358,341
-15,430
-4% -$1.07M 0.02% 418
2021
Q4 		$31.4M Buy
373,771
+129,824
+53% +$10.6M 0.03% 401
2021
Q3 		$22M Buy
243,947
+9,587
+4% +$867K 0.02% 449
2021
Q2 		$18.7M Buy
234,360
+7,093
+3% +$739K 0.02% 495
2021
Q1 		$25.9M Buy
227,267
+46,789
+26% +$6.37M 0.03% 415
2020
Q4 		$25M Buy
180,478
+43,636
+32% +$5.18M 0.03% 390
2020
Q3 		$11.2M Buy
136,842
+26,500
+24% +$2.2M 0.02% 514
2020
Q2 		$8.63M Buy
110,342
+39,326
+55% +$2.6M 0.01% 544
2020
Q1 		$3.15M Sell
71,016
-54
-0.1% -$2.8K 0.01% 730
2019
Q4 		$3.04M Sell
71,070
-4,100
-5% -$169K ﹤0.01% 830
2019
Q3 		$3.22M Sell
75,170
-8,000
-10% -$435K ﹤0.01% 792
2019
Q2 		$5.28M Buy
83,170
+18,350
+28% +$1.17M 0.01% 673
2019
Q1 		$4.5M Buy
64,820
+7,281
+13% +$416K 0.01% 719
2018
Q4 		$2.5M Sell
57,539
-1,600
-3% -$87.4K ﹤0.01% 852
2018
Q3 		$4.51M Sell
59,139
-242
-0.4% -$19.7K 0.01% 763
2018
Q2 		$4.57M Buy
59,381
+13,387
+29% +$865K 0.01% 738
2018
Q1 		$2.35M Buy
45,994
+4,666
+11% +$235K ﹤0.01% 856
2017
Q4 		$1.92M Buy
41,328
+9,700
+31% +$476K ﹤0.01% 897
2017
Q3 		$1.69M Sell
31,628
-6,100
-16% -$361K ﹤0.01% 915
2017
Q2 		$2.34M Buy
37,728
+1,600
+4% +$96.4K ﹤0.01% 840
2017
Q1 		$2.45M Sell
36,128
-2,600
-7% -$198K ﹤0.01% 848
2016
Q4 		$2.72M Buy
38,728
+100
+0.3% +$7.09K ﹤0.01% 803
2016
Q3 		$2.74M Buy
38,628
+5,409
+16% +$345K ﹤0.01% 814
2016
Q2 		$1.63M Buy
33,219
+5,954
+22% +$385K ﹤0.01% 887
2016
Q1 		$1.73M Sell
27,265
-1,000
-4% -$65.4K ﹤0.01% 866
2015
Q4 		$3.17M Sell
28,265
-700
-2% -$70K 0.01% 759
2015
Q3 		$2.79M Buy
28,965
+4,531
+19% +$519K 0.01% 765
2015
Q2 		$2.5M Hold
24,434
– – ﹤0.01% 816
2015
Q1 		$1.52M Buy
24,434
+2,000
+9% +$111K ﹤0.01% 871
2014
Q4 		$984K Buy
22,434
+3,550
+19% +$163K ﹤0.01% 937
2014
Q3 		$1.07M Buy
+18,884
New +$950K ﹤0.01% 894
2014
Q2 		– Sell
-5,800
Closed -$284K – 1311
2014
Q1 		$284K Buy
+5,800
New +$299K ﹤0.01% 1164

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

TD Asset Management's RARE Position: Q1 2026 in Review

TD Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 81,964 shares — an estimated $1.89M sold.

TD Asset Management first reported a position in RARE in Q1 2014 and held it in 47 quarters. The position peaked at $31.4M in Q4 2021. 297 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • TD Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • TD Asset Management sold 81,964 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $1.89M.
  • TD Asset Management first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and held it in 47 quarters.
  • TD Asset Management's Ultragenyx Pharmaceutical position peaked at $31.4M in Q4 2021.
  • 297 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on TD Asset Management's 13F filing for Q1 2026, filed 11 May 2026.